ArticleMetabolic brain disease2026
Exploring the potential of resveratrol-enriched cord mesenchymal stem cell derived exosomes in an in vitro Parkinson's model.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra and the pathological aggregation of α-synuclein (α-syn) into Lewy bodies and it is known as the second most prevalent neurodegenerative disorder. The pathogenesis of PD involves mitochondrial dysfunction, oxidative stress, impaired protein degradation, and neuroinflammation. Current therapeutic strategies are largely symptomatic and remain limited in their ability to halt disease progression. Resveratrol (Res) has been shown to mitigate oxidative stress, preserve mitochondrial integrity, and reduce α-syn aggregation in PD models due to its antioxidant and neuroprotective properties. Despite its promising therapeutic potential, its poor bioavailability and rapid metabolism hinder the achievement of the desired therapeutic effects, which calls for advanced drug delivery systems. Human umbilical cord-derived mesenchymal stem cell (hUC-MSC) exosomes (Exos) are nanoscale extracellular vesicles with intrinsic neuroprotective, anti-inflammatory, and regenerative properties. They represent a promising carrier system owing to biocompatibility and the ability to cross the blood-brain barrier. Since the isolation technique is a critical parameter affecting both Exos yield and therapeutic efficacy, the study initially focused on optimizing the isolation process through a comparative investigation of ultracentrifugation and commercial isolation kits. Exos obtained with the highest yield and optimal characteristics, were subsequently subjected to Res loading through the probe sonication method. After the physicochemical characterization of Res-loaded exosomes (Exo-Res), their therapeutic potential was evaluated in an in vitro PD model established by rotenone-induced neurotoxicity in SH-SY5Y cells. Cell viability, oxidative stress, mitochondrial function, and whole protein aggregation were comprehensively assessed. Exo-Res isolated with Kit-1 showed a smaller particle size (94.0 nm) with high homogeneity (PDI < 0.3), high yield (3.9 × 10
Indexed as
Identifiers
42878928What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.